BE530472A - - Google Patents
Info
- Publication number
- BE530472A BE530472A BE530472DA BE530472A BE 530472 A BE530472 A BE 530472A BE 530472D A BE530472D A BE 530472DA BE 530472 A BE530472 A BE 530472A
- Authority
- BE
- Belgium
- Prior art keywords
- adrenochrome
- weight
- mono
- para
- oxime
- Prior art date
Links
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 31
- 239000000243 solution Substances 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 21
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 12
- 159000000000 sodium salts Chemical class 0.000 claims description 12
- 230000002439 hemostatic Effects 0.000 claims description 11
- XSXCZNVKFKNLPR-SDQBBNPISA-N Carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 230000003000 nontoxic Effects 0.000 claims description 5
- 231100000252 nontoxic Toxicity 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 2
- 229960002631 carbazochrome Drugs 0.000 claims 4
- 150000003863 ammonium salts Chemical class 0.000 claims 2
- 159000000001 potassium salts Chemical class 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010018987 Haemorrhage Diseases 0.000 description 6
- 230000000740 bleeding Effects 0.000 description 6
- 231100000319 bleeding Toxicity 0.000 description 6
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 4
- 150000007659 semicarbazones Chemical class 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- 210000001736 Capillaries Anatomy 0.000 description 2
- 229940012952 Fibrinogen Drugs 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 229940019698 Fibrinogen containing hemostatics Drugs 0.000 description 2
- NRZRRZAVMCAKEP-UHFFFAOYSA-N Naphthionic acid Chemical compound C1=CC=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 NRZRRZAVMCAKEP-UHFFFAOYSA-N 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 1
- 210000001772 Blood Platelets Anatomy 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- -1 ammonium cations Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE530472A true BE530472A (sv) |
Family
ID=163113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE530472D BE530472A (sv) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE530472A (sv) |
-
0
- BE BE530472D patent/BE530472A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0316993B1 (fr) | Compositions pharmaceutiques contenant un dérivé de l'acide 3-hydroxybutanoique choisi parmi les oligomères de cet acide et les esters de cet acide ou de ces oligomères avec du 1,3-butanediol | |
| EP0399903A1 (fr) | Nouvelles compositions à base d'imipramine | |
| CH469659A (fr) | Procédé d'obtention de dérivés du tri-hydroxy-méthyl-aminométhane | |
| CH646412A5 (fr) | Procede de preparation des produits hydrosolubles a base de (+)-catechine et compositions contenant ces produits. | |
| FR2522501A1 (fr) | Isothiosemicarbazones antivirales et leur utilisation pour prevenir une infection fongique | |
| FR2460672A1 (fr) | Preparation de poudre d'acetylsalicylate pour injection | |
| MX2013008151A (es) | Un procedimiento para fabricar un complejo mejorado de cloruro de bencetonio-dialil oxido de disulfuro modificado el complejo obtenido y sus usos. | |
| CA1312333C (fr) | Sel de strontium, son procede de preparation et les compositions pharmaceutiques le renfermant | |
| BE530472A (sv) | ||
| JPS5835967B2 (ja) | 微細結晶ワルフアリンの製造方法 | |
| EP0575481B1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4 | |
| CH664284A5 (en) | Chloroquine medicaments without bitter taste - contain complex of chloroquine with copolymer of methacrylic] acid and methyl methacrylate] | |
| BE1000189A3 (fr) | Preparation pharmaceutique a usage veterinaire. | |
| WO1981002295A1 (fr) | Phenoxyisobutyrates de moroxydine et medicaments les contenant | |
| BE528966A (sv) | ||
| FR2616068A1 (fr) | Procede de stabilisation des principes actifs de produits vegetaux et les compositions pharmaceutiques renfermant lesdits principes actifs stabilises | |
| LU84530A1 (fr) | Procede de preparation d'acide p-butoxyphenylacethydroxamique a l'etat finement divise et composition contenant cet acide | |
| BE528056A (sv) | ||
| BE887220A (fr) | Compositions antitumeurs | |
| BE903568A (fr) | Nouveaux composes chimiques a activites antiphlogistiques, antiseptiques et detergentes | |
| BE568289A (sv) | ||
| BE876544A (fr) | Composes de type acide p-aminobenzoique-n-l-rhamnoside utiles comme medicaments | |
| BE572443A (sv) | ||
| BE536866A (sv) | ||
| BE875186A (fr) | 2-(2-thenoylthio)-propionyglycine, procede pour sa preparation et compositions pharmaceutiques la contenant |